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The manifestation of mitochondrial DNA (mtDNA) diseases depends
on the frequency of heteroplasmy (the presence of several alleles
in an individual), yet its transmission across generations cannot
be readily predicted owing to a lack of data on the size of the
mtDNA bottleneck during oogenesis. For deleterious heteroplas-
mies, a severe bottleneck may abruptly transform a benign (low)
frequency in amother into a disease-causing (high) frequency in her
child. Here we present a high-resolution study of heteroplasmy
transmission conducted on blood and buccal mtDNA of 39 healthy
mother–child pairs of European ancestry (a total of 156 samples,
each sequenced at ∼20,000× per site). On average, each individual
carried one heteroplasmy, and one in eight individuals carried a dis-
ease-associated heteroplasmy, with minor allele frequency ≥1%.
We observed frequent drastic heteroplasmy frequency shifts be-
tween generations and estimated the effective size of the germ-
line mtDNA bottleneck at only ∼30–35 (interquartile range from 9
to 141). Accounting for heteroplasmies, we estimated the mtDNA
germ-line mutation rate at 1.3 × 10−8 (interquartile range from 4.2 ×
10−9 to 4.1× 10−8) mutations per site per year, an order of magnitude
higher than for nuclear DNA. Notably, we found a positive association
between the number of heteroplasmies in a child andmaternal age at
fertilization, likely attributable to oocyte aging. This study also took
advantage of droplet digital PCR (ddPCR) to validate heteroplasmies
and confirmadenovomutation.Our results canbeused topredict the
transmission of disease-causing mtDNA variants and illuminate
evolutionary dynamics of the mitochondrial genome.
mitochondria | heteroplasmy
The centerpiece of cellular metabolic machinery—the mito-chondrion—harbors a 16.5-kb genome, mitochondrial DNA
(mtDNA). Mutations in mtDNA cause over 200 diseases and
contribute to diabetes, cancer, male infertility, Parkinson’s and
Alzheimer’s diseases (1). In mammals, mtDNA mutates at high
rates and is maternally inherited, making it a popular marker in
evolutionary genetics (2). Despite its importance, mtDNA has
drifted away from the spotlight eclipsed by nuclear DNA studies
(3), and there are still gaps in our understanding of the basic as-
pects of human mtDNA biology. The lack of cures for diseases
caused by mtDNA mutations makes it critical to understand how
these mutations arise and are transmitted between generations.
Heteroplasmy, the presence of more than one mtDNA variant
in a cell or a tissue, is the result of a de novo mtDNA mutation
occurring in an individual or inherited through the maternal line-
age. Currently there is no consensus about how prevalent mtDNA
heteroplasmy is in human populations (4, 5). Such knowledge is
crucial for assessing the load of mtDNA pathogenic mutations,
formulating prognoses for patients with mtDNA diseases, and
preimplantation diagnostics after mtDNA replacement in oocytes.
Most mtDNA diseases are heteroplasmic and their phenotype de-
pends on the allele frequency of the pathogenic variant (1).
Heteroplasmy levels can change dramatically between gen-
erations owing to genetic drift during the germ-line bottleneck—a
reduction in the number of mtDNA segregating units during
oogenesis (6–8). The size of the bottleneck for mice has been
evaluated to be 185 (9), yet for humans this size is difficult to
obtain experimentally. Published estimates of the human bot-
tleneck size are too broad [1–200 (10, 11)] to be useful in pre-
dicting the transmission of disease variants. Genetic drift theory
predicts that a small bottleneck size will result in drastic shifts in
heteroplasmy levels from a mother to her child, potentially reach-
ing nondisease levels or levels with higher disease severity. After
fertilization, mtDNA variants are distributed among cells owing to
mitotic segregation—the random partitioning of mitochondria
during cell divisions (12). We also lack an accurate estimate of the
germ-line mtDNA mutation rate in humans, with pedigree and
phylogenetic studies producing conflicting results (13, 14).
To conduct a population study of heteroplasmy transmission, we
analyzed full-length mtDNA in 39 mother–child pairs using the
MiSeq platform. Accounting for PCR and sequencing errors, we
were able to accurately score heteroplasmies with allele frequency
above 1%. With these data, we addressed (i) how common hetero-
plasmy is in a human population, (ii) how heteroplasmy frequency
changes between tissues of the same individual and between gen-
erations, and (iii) whether maternal age at conception influences
heteroplasmy occurrence in a child. We also estimated the size of
the germ-line mtDNA bottleneck and the germ-line mutation rate
via population genetics modeling of heteroplasmies. Focused on
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heteroplasmy inheritance in healthy individuals, our data serve as
a valuable baseline to study disease associations for mtDNA and
provide important insights into mtDNA evolution.
Results
Samples, mtDNA Enrichment, and Sequencing. We studied the prev-
alence of mtDNA heteroplasmy in blood and buccal cells from 39
mother–child pairs residing in central Pennsylvania, analyzing 156
samples (39 mothers × 2 tissues + 39 children × 2 tissues) grouped
in sets of four (two tissues from a mother and two tissues from her
child). Total genomic DNA was isolated from each sample. Hap-
logroup analysis conducted via Sanger sequencing of the D-loop
indicated European ancestry for all families (Dataset S1, Table
S1). For each sample, we amplified mtDNA from total DNA in
two overlapping 9-kb fragments and sequenced them with paired-
end 250-bp reads on a MiSeq instrument (Materials and Methods).
This enriched for mtDNA and minimized the presence of numts
(Fig. S1 and SI Materials and Methods), the majority of which are
short (15). Multiplexing 12 samples per run resulted in ∼106 read
pairs per sample. We confirmed the efficacy of our approach for
mtDNA enrichment by applying it to Rho0 cells not harboring
mitochondria (Fig. S2). To minimize potential contamination
among samples, we followed previously devised guidelines (16) and
used pUC18 and PhiX174 as spike-ins (Materials and Methods).
Heteroplasmy Discovery. The sequencing read pairs were mapped
to human mtDNA and nuclear genomes. On average, 85% of the
reads per sample mapped to mtDNA (97% for samples without
a spike-in; Fig. S3). We then applied our heteroplasmy discovery
pipeline (Materials and Methods and Fig. S4). We required both
reads of the pair to map uniquely, and in a proper orientation, to
the reference mtDNA (Fig. S5). To compute minor allele fre-
quency (MAF) at each site for each sample, we used bases with se-
quencing quality ≥30 from reads with mapping quality ≥20 (other
thresholds led to almost identical results; Fig. S6). The mean
sequencing depth per sample (averaged across sites) was 19,789× ±
770× (mean ± SEM). Tabulating depth on a per-site basis, 90% of
sites in the mitochondrial genome were sequenced at ≥7,858× per
sample (Fig. S7). The proportion of spike-in reads aligning to their
respective references was as anticipated, suggesting absence of
contamination among adjacent samples (Fig. S3).
In the search for heteroplasmies, we first identified sites with
MAF ≥1% in individual samples. The sequencing depth per site
required to detect true heteroplasmies with MAF ≥1% over the
base quality error (0.1% for Phred score 30) with 99% power is
839× per site (one-sided power calculation for one-sample pro-
portion test). Conservatively, we rounded up the depth requirement
to 1,000×. A detection limit of MAF ≥1% allows detection of in-
herited and de novo variants that pass through the bottleneck if its
size is <100. Mutations with lower frequency are accounted for
with population genetics modeling (discussed below). After fil-
tering for potential sequencing artifacts (Dataset S1, Table S2 and
Materials and Methods), we identified 174 point heteroplasmies
distributed among 100 quartets—groups of site-specific hetero-
plasmy frequencies from two tissues of a mother and two tissues
from her child (Dataset S1, Table S3). These heteroplasmies were
found in 31 families (eight families had no heteroplasmies).
Statistical Validation of Point Heteroplasmies. To validate hetero-
plasmies, we used a novel statistical method that identifies hetero-
plasmic sites via a likelihood function accounting for instrument
sequencing andmapping errors (SIMaterials andMethods).With this
method, all 174 point heteroplasmies were significant (P< 0.0003 for
each site; Dataset S1, Table S4). Additionally, the allele counts for all
174 heteroplasmies tested were significant (P < 0.0003 for 172 sites,
and P < 0.03 for the remaining two sites; Table S4) based on the
variability observed for the same position among all samples (17).
Experimental Validation of Point Heteroplasmies. We used Sanger
sequencing to test all point heteroplasmies with MiSeq MAF ≥10%
(Sanger method detection limit, Fig. S8A and Dataset S1, Table S5)
in at least one sample per family and the corresponding sites from
the other samples from the same family (we always sequenced newly
amplified fragments). In total, we examined 21 sites × 4 samples =
84 sites, 44 of which hadMiSeqMAF≥10% (Dataset S1, Table S6).
The presence of heteroplasmy was successfully validated in all these
44 cases. Thus, our false-positive rate for detecting heteroplasmies
with MAF ≥10% is below 0.023 (1/44). The MAFs from the MiSeq
and Sanger methods were well correlated (R2 = 75%; Fig. S9A).
A set of point heteroplasmies with MiSeq MAF <10% was
analyzed with droplet digital PCR (ddPCR) (18), which can detect
heteroplasmies withMAF>0.2% (Fig. S8B andC andDataset S1,
Table S7). Here we analyzed point heteroplasmies with MiSeq
MAF between 1% and 10% in at least one sample per family and
the corresponding sites from the other samples of the same family,
a total of 10 sites × 4 samples = 40 sites, 18 of which had MiSeq
MAF ≥1% (Fig. S9B and Dataset S1, Table S8). When we assayed
the original amplicons used forMiSeq sequencing, the presence of
heteroplasmy was confirmed in all these 18 instances. However,
when we reamplified mtDNA from these 18 samples, in two in-
stances (site 11,616 in M203C5-ch and site 11,825 in M210-bl)
ddPCR did not confirm the presence of heteroplasmy. Repeating
amplification and ddPCR for a third time again did not detect
heteroplasmy (Dataset S1, Table S8), suggesting PCR errors in the
amplicons sequenced with MiSeq. Thus, our false-positive rate for
detecting heteroplasmies with MAF between 1% and 10% is 0.11
(2/18). Overall, the MAFs from the MiSeq and ddPCR methods
were well correlated for the sequenced and newly amplified
amplicons (R2 = 95% and 79%, respectively; Fig. S9B).
Distribution of Point Heteroplasmies. After removing two sites that
failed to validate with ddPCR (discussed above), we retained 172
point heteroplasmies in 98 quartets (Dataset S1, Table S3). We
assumed that these 98 point mutations arose independently in the
families analyzed (or in their maternal ancestors). Point hetero-
plasmies were found at 87 unique mtDNA positions (Fig. S10).
Six positions (185, 189, 214, 215, 16,093, and 16,183) were het-
eroplasmic in multiple families (four, three, three, two, three, and
two families, respectively; Dataset S1, Table S3), likely owing to
high mutation rate at the D-loop (13). Each mother on average
carried 1.13 ± 0.04 heteroplasmies in her blood. This value was
similar for maternal buccal tissue and for buccal and blood tissues
of children (Fig. S11). Among the 98 point heteroplasmies 96
were transversions, resulting in a transition-to-transversion ratio
of 48 (Fig. S10 and Dataset S1, Table S3).
There were significantly more and significantly fewer hetero-
plasmies in the D-loop and protein-coding regions, respectively,
than expected based on their length and assuming equal pro-
pensity to harbor a heteroplasmy along mtDNA (Table 1). A high
mutation rate for the D-loop had been documented previously
(13). The nonsynonymous-to-synonymous rate ratio (dN/dS)
at (concatenated) protein-coding genes was significantly
lower than 1 (P = 5 × 10−3; Fisher’s exact test; Dataset S1,
Table S9), suggesting purifying selection (19). Most non-
synonymous mutations were predicted to affect protein
function (Dataset S1, Table S10).
Disease-Associated Mutations and Mutation Burden. Eight families
harbored eight point heteroplasmies (one per family) that can
cause disease when present at high allele frequencies (Table 2).
Among 39mothers, 5 (or 1 in 8) were carriers of disease-associated
mtDNA mutations in at least one of the two tissues analyzed.
Mutations at four of the eight sites are associated with disease
when homoplasmic for the mutant allele (20–23); however, in our
data these were heteroplasmic (Table 2). For the other four of the
eight sites above, disease can develop even whenmutant alleles are
heteroplasmic—with disease severity depending on the allele fre-
quency. ForA1555G,G13708A, andG3242Amutations, the allele
frequencies were much lower than disease-associated frequencies
(Table 2) (24–26), suggesting lack of symptoms. Mutations at
tRNA-Leu sites 3,242 and 3,243 contribute to several mitochon-
drial diseases (25, 27); notably, allele frequencies observed at site
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3243 in the child of family M512 (Table 2) were comparable to
those observed in mitochondrial encephalomyopathy, lactic aci-
dosis, and stroke-like episodes patients (27).
Transmission of Heteroplasmies. Considering heteroplasmy-con-
taining quartets (Dataset S1, Table S3), we used the presence of
heteroplasmy with MAF ≥1% in at least one sample from
a family as a “prior” to support the existence of heteroplasmy at
the same position for other samples of the same family if their
MAF was ≥0.2% (greater than or equal to twice the value of the
allowed sequencing quality error of 0.1%—Phred score 30). We
classified 98 quartets into five categories (Table 3 and Dataset
S1, Table S3) based on whether heteroplasmies were present in
(i) both tissues of a mother and both tissues of her child (category
“all,”which included dramatic shifts in allele frequency frommother
to child, suggesting the germ-line bottleneck); (ii) both tissues of a
mother, but absent fromboth tissues of her child (category “mother,”
suggesting loss of a variant in the child owing to the germ-line bot-
tleneck); (iii) both tissues of a child, but absent from both tissues of
a mother (category “child” with candidate germ-line de novo mu-
tations); (iv) both tissues of a mother and one tissue of a child, or in
one tissue of amother and both tissues of a child (category “somatic
loss,” suggestive of a change in MAF in tissues owing to mitotic
segregation) (12); and (v) one tissue of one individual of a family
(category “somatic gain”with candidate somatic de novomutations).
Site 4191 in family M500 seemed to harbor a de novo mutation
in the child. ddPCR confirmed complete absence of the mutant
allele in both maternal tissues but presence in both tissues of the
child (with MAF of 4.7% and 5.6% in buccal and blood tissues,
respectively; Table 3 and Dataset S1, Table S8). Examination of
hair from the same individuals indicated homoplasmy in the
mother and MAF of 1.2% in the child (Dataset S1, Table
S11), confirming emergence of a novel allele.
The changes in allele frequencies between tissues of an in-
dividual, or between two generations, tabulated for our 98 quartets
(Dataset S1, Table S3) followed an approximately normal distri-
bution with mean zero (Fig. S12), corroborating the action of
genetic drift as the major force affecting heteroplasmy allele
frequencies (28). A decrease in allele frequency for a variant from
mother to child will be indicative of purifying selection (29). When
we plotted the relative change in allele frequency between mothers
and children (Fig. S13), such a decrease was significant for nonsyn-
onymous sites (P = 9.54 × 10−7, one-tailed nonparametric sign test),
suggestive of purifying selection. Consistent with selection operating
against transmission of nonsynonymous mutations, we observed
a significantly lower proportion of these mutations among trans-
mitted heteroplasmies (5 out of 43, or 12%, in “all” and “somatic
loss” categories) comparedwith untransmitted heteroplasmies (8 out
of 22, or 36%, in “mother” category; P = 0.025, Fisher’s exact test).
Comparing MAFs Between Tissues and Generations. Compared with
mtDNA in maternal tissues, mtDNA in child tissues underwent
fewer mitotic segregations and replications and was exposed to
mutagens for a shorter time. Therefore, we expect heteroplasmy
allele frequency at a site to diverge less in the tissues of a child than in
those of a mother. Indeed, the allele frequencies for the sites tabu-
lated as quartets (Dataset S1, Table S3) were more strongly corre-
lated between the two tissues for children (R2 = 92%, Fig. 1A) than
between the two tissues for mothers (R2 = 49%, Fig. 1B). Stronger
correlation for allele frequencies was observed between two tissues
of a mother or of a child (discussed above) than between a mother
and a child for the same tissue (R2 = 13% for buccal, Fig. 1C; R2 =
29% for blood, Fig. 1D), likely owing to the stronger action of the
mtDNA germ-line bottleneck relative to mitotic segregation.
Maternal Age Effect.We explored the relationship between age and
the total number of point heteroplasmies for each individual. No
association was found for children. For mothers we found a sig-
nificant positive association (P = 0.039, 0.049, and 0.055 for com-
bined, buccal, and blood heteroplasmies, respectively, Poisson
regression; Fig. 2 and Fig. S14). Thus, older mothers accumulate
more mutations in their somatic tissues, with the number of point
heteroplasmies tripling over 30 y of life. Intriguingly, a positive as-
sociation exists between the number of heteroplasmies in children
and maternal age at fertilization (P = 0.010, 0.005, and 0.006, for
combined, buccal, and blood heteroplasmies, respectively; Fig. 2
and Fig. S14). This suggests that older mothers accumulate more
mutations in their germ-line tissues. In our dataset, there was a
correlation between maternal age at fertilization and maternal age
Table 1. The distribution of point heteroplasmies among
mtDNA regions
Region bp Observed Random Neutral
D-loop 1,122 34 6.6* 7.9*
tRNA 1,508 6 8.9 10.6
rRNA 2,513 13 14.9 17.7
Protein S 2,834 20 16.8 20.0
Protein N 8,533 25 50.5* 60.2*
Intergenic 88 0 0.5 0.6
Total 16,569† 98 N/A 197
The observed numbers of heteroplasmies and the numbers expected under
random and neutral (based on the frequency at synonymous sites) expect-
ations are shown. The numbers of synonymous (S) and nonsynonymous (N)
sites were calculated with the Nei–Gojobori method. N/A, not applicable.
*Significantly different from observed (P< 0.05, test comparing two proportions).
†Owing to overlapping annotations and exclusion of stop codons, the sum of
base pairs in regions does not sum up to the overall length of mtDNA.
Table 2. Disease-causing heteroplasmies
Site Region
Wild
type Mutant
Amino
acid
change Family
Mother
cheek
Mother
blood
Child
cheek
Child
blood
Diseases caused
by the mutant allele
Disease allele
frequency
(ref.)
195 D-loop T C — M494 0.084 0.012 0.002 0.001 Bipolar disorder 1.0 (20)
1,391 12S T C — M513 0.040 0.027 0.001 0.000 HCM 1.0 (21)
1,555 12S A G — M520 0.002 0.001 0.014 0.014 Deafness >0.52 (24)
2,352 16S C T — SC16 0.429 0.437 0.247 0.245 LVNC 1.0 (22)
3,242 Leu G A — M242 0.001 0.001 0.008 0.016 RTD >0.49 (25)
3,243 Leu A G — M512 0.335 0.144 0.686 0.611 MELAS, MIDD; MERRF;
CPEO
>0.5 (27)
12,634 ND5 A G I to V M203 0.001 0.025 0.001 0.001 Thyroid cancer
(cell line)
1.0 (23)
13,708 ND5 G A A to T SC8 0.001 0.000 0.022 0.016 LHON >0.92 (26)
The allele frequencies for themutant allele in maternal and child tissues are indicated. CPEO, chronic progressive external ophthalmoplegia; HCM, hypertrophic
cardiomyopathy; LHON, Leber’s hereditary optic neuropathy; LVNC, left ventricular noncompaction; MELAS, mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes; MERRF, myoclonic epilepsy with ragged-red fibers; MIDD, maternally inherited diabetes deafness; RTD, renal tubular dysfunction.
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at sampling (R2 = 43%, P = 0.002, linear regression), and we
found that older mothers, who also had children later, likely trans-
ferred a larger number of accumulated mutations to their children
(Fig. 2); whereas mothers who conceived under the age of 20
transmitted zero to one heteroplasmies, this number was two to
three for mothers conceiving in their late 30s.
Estimating the Size of the Germ-Line mtDNA Bottleneck and Mutation
Rate. Because most heteroplasmy allele frequency changes be-
tween the two generations are consistent with genetic drift (Fig.
S12), we can estimate the effective size of the germ-line bottle-
neck, that is, the size of the bottleneck in a traditional population
model required to explain the observed amount of genetic drift
[the actual number of mtDNA molecules passing through the
bottleneck might be different, because they might segregate in
units (8)]. Following the method developed by Millar, Hendy,
and coworkers (30, 31), we assume that a child samples mutant
mtDNA alleles at a given site from a binomial distribution with
parameters p, the maternal MAF in the germ line (estimated
here from somatic tissues), and N, the germ-line bottleneck size
(SI Materials and Methods). Then the variance of the child’s het-
eroplasmy frequency at conception, or genetic variance, is σ2gen =
p(1 − p)/N. Solving for N, we obtain N = p(1 − p)/σ2gen. We es-
timate the genetic variance as σ2gen = σ2raw − 4σ2measure, where
σ2raw is the squared difference between the maternal and the child
MAF at the site and σ2measure is the uncertainty in measuring
heteroplasmy frequency (includes sampling, PCR, and sequencing
errors), which we estimated from sequencing amplified D-loop–
containing clones (SI Materials and Methods; σ2measure was multi-
plied by 4 because we are taking four measurements). This pro-
cedure produced an estimate of N in a quartet. To minimize false
positives, we applied this approach to quartets where hetero-
plasmy was present in both maternal tissues (51 quartets in which
at least one tissue in the mother had heteroplasmy with MAF
≥1% and the other tissue had MAF ≥0.2%; Dataset S1, Table S3),
and thus likely was present in the maternal germ line. The me-
dian estimated N across these 51 quartets, when MAFs were
averaged between the two maternal tissues and (separately) be-
tween the two child tissues, was 32.3 [interquartile range (IQR)
10.5–103.3; Fig. S15]. Similar estimates of bottleneck size were
obtained when only blood (median N = 33.5, IQR 14.1–79.6) or
only buccal tissues were used (median N = 29.8, IQR 9.5–68.1),
and when quartets with nonsynonymous mutations were ex-
cluded (median N = 31.9, IQR 8.8–99.2). Accounting for the
variance owing to mitotic segregation (SI Materials and Methods)
led to median N = 35.0 (IQR 10.0–141.4; Fig. S15). Also, as-
suming that the single germ-line mutation we observe (at site
4191 in family M500, Table 3) originated in a single mtDNA
segregating unit in the maternal germ line, and that its MAF in
the child’s zygote was 3.8% (averaged across three tissues), we
can estimate N as 1/0.038 = 26.3.
Next, we estimated the mtDNA germ-line mutation rate μ
as in Millar, Hendy, and coworkers (30, 31). Assuming that
new mutations enter the germ line at rate α, and that they are
neutral and have equal probability to be transmitted to the next
generation, only 1/N of them will go to fixation, leading to μ =
α/N. A heteroplasmy can only be observed when its MAF is above
a detection threshold θ. Analytically, it was shown (30, 31) that
most heteroplasmies are lost without reaching θ, that most het-
eroplasmies reaching θ do not go to fixation, and that the rate of
observed heteroplasmies can be approximated as μ0 = 2αln(1/θ −
1). Solving for α, one obtains α = μ0/(2 ln(1/θ − 1)). Thus, μ =
μ0/(2N ln(1/θ − 1)). Setting θ = 0.01 (our detection threshold)
results in μ = 0.109 μ0/N. Having observed 51 germ-line point
heteroplasmies among 39 mothers, we estimated μ0 as 51/(39 ×
16,569 bp) = 7.9 × 10−5 heteroplasmies per transmission per site.
Using N = 32.3, we thus estimated the mutation rate μ as 2.7 × 10−7
mutations per site per generation (IQR 8.3 × 10−8 to 8.2 × 10−7),
or, assuming a generation time of 20 y, 1.3 × 10−8 mutations per
site per year (IQR 4.2 × 10−9 to 4.1 × 10−8). The mutation rate
estimate excluding nonsynonymous sites was 4.4 × 10−7 mutations
per site per generation (IQR 1.4 × 10−7 to 1.6 × 10−6), or 2.2 × 10−8
mutations per site per year (IQR 7.0 × 10−9 to 7.9 × 10−8). That for
the D-loop was 1.5 × 10−6 mutations per site per generation
(IQR 4.8 × 10−7 to 4.7 × 10−6), or 7.7 × 10−8 mutations per site per
year (IQR 2.4 × 10−8 to 2.4 × 10−7).
Indel Heteroplasmies. Using the same thresholds (MAF ≥1% and
depth >1,000×), we identified 120 instances of small indels af-
fecting 10 unique mtDNA sites and 28 families (Dataset S1, Table
S12 and SI Materials and Methods). All indels occurred in repeats—
eight in homopolymer runs, one in a 9-bp tandem repeat, and one
in a CA repeat. The latter indel was validated with ddPCR
(Dataset S1, Table S13). The MAFs of indels in our samples were
above microsatellite sequencing errors for our long-range PCR
protocol (SI Materials and Methods). Further experimental vali-
dation will allow us to determine indel MAFs more accurately.
Discussion
Prevalence of Heteroplasmy in Humans. mtDNA heteroplasmy has
strong associations with neurodegenerative diseases, aging, and
tumorigenesis (1). Our results indicate that an individual carries
on average one heteroplasmic variant with allele frequency ≥1%
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Fig. 1. Correlation in heteroplasmy allele frequencies between (A) the two
tissues of children, (B) the two maternal tissues, (C) buccal tissues of mothers
and children, and (D) blood of mothers and children.
Table 3. Categories of quartets with examples
Category Total Family Site mj mn
M
cheek
M
blood
C
cheek
C
blood
All 22 (11,−) M188 5,107 C T 0.152 0.165 0.228 0.225
Child 16 (2,3) M500 4,191 A T 0.000 0.000 0.047 0.056
Mother 22 (4,5) M494 9,196 G A 0.032 0.030 0.000 0.000
SG 13 (−,2*) M137 8,953 A G 0.000 0.013 0.000 0.000
SL 25 (4,−) M236 6,791 A G 0.002 0.000 0.015 0.015
The total number of quartets (with the number validated with Sanger
sequencing and ddPCR in parentheses, asterisk indicates failed validations),
followed by an example with family, site, major (mj) andminor (mn) alleles, and
MAFs in maternal (M) and child (C) tissues. SG, somatic gain; SL, somatic loss.
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pointing to the ubiquitous occurrence of heteroplasmy (4) and
are in remarkable agreement with a recent analysis of the 1,000
Genomes Project data (19) as well as several smaller-scale studies
(5, 11, 32–34) (Dataset S1, Table S14).
Maternal Age Effect. A positive association between an individu-
al’s age and the number of heteroplasmies in postmitotic somatic
tissues had already been demonstrated (e.g., refs. 35 and 36).
Here, we found evidence for it in the dividing tissues as well.
Kennedy et al. (35) found that the frequency of point mutations
in brain increases fivefold during 80 y of life. In our data, the
number of heteroplasmies in the maternal buccal and blood tissues
triples over 30 y. Likewise, with high transition-to-transversion ratio
in our data, we do not find transversion-causing oxidative damage
(37) to be the major driver of such mutation accumulation.
The positive association we found between maternal age at
conception and the number of heteroplasmies in her child has
important medical implications. The frequencies of large mito-
chondrial deletions (38) and the T414G mutation (39) were shown
to increase in oocytes as a function of age—consistent with altered
mitochondrial cytochemistry and a mutagenic environment with
increased glycation and carbonyl stress in aging oocytes (40).
However, the number of oocytes with defective mitochondria is
significantly reduced during oogenesis (41). Our results suggest
that, despite this process, some oocytes with suboptimal mito-
chondria (e.g., with negatively selected amino acid changes),
which are more likely to occur in older women, do proceed to
fertilization. This predicts an increase in mtDNA diseases in
children born to older mothers—a prediction not evaluated to
date—and could be one of the reasons for a lower success rate of
assisted reproduction in older women (42).
Germ-Line Bottleneck Size. Our results support a severe germ-
line bottleneck—with effective size of only 30–35—and are
particularly striking given ∼100,000 mtDNAs in mature hu-
man oocytes (12). Our findings corroborate strong shifts in
heteroplasmy frequency observed in Holstein cows (43, 44)
but are more robust because they are based on more accurate
estimation of MAF changes at many sites, in two tissues, and for
a large number of transmissions from multiple families. Moreover,
results obtained for other species are not directly applicable to
humans, especially for the purposes of genetic counseling. Most
previous human studies analyzed one or two sites, some of which
were disease-associated, and usually a small number of trans-
missions (Dataset S1, Table S15). Our estimate is comparable to
those in some earlier studies [e.g., 36–180 (45)], higher than in
some other studies [e.g., 1–5 (10)], but substantially lower than
the recently proposed estimate of 200 (11).
The number 30–35 is obtained by taking medians over effec-
tive bottleneck sizes estimated for individual transmission sites,
which show a broad variation (Fig. S15). Some of this variation is
random, because only one transmission was examined for each
site. Selection acting at some sites might have contributed to this
variation as well; however, the median bottleneck size remained
very similar when nonsynonymous sites were removed. Another
contributor to the observed variation in bottleneck size might be
the variation among women (46, 47). Future studies examining
multiple offspring per mother will allow one to evaluate the
differential contribution of these factors to the variability in the
bottleneck size in more detail.
Germ-Line Mutation Rate. The germ-line mutation rate estimated
here for mtDNA is an order of magnitude higher than that for
the human nuclear genome [1.2 × 10−8 mutations per site per
generation (48)], in agreement with previous studies (1). It is
similar to estimates obtained in phylogenetic studies (e.g., refs.
13 and 14) and an order of magnitude lower than estimates in
most pedigree studies (13, 49–51) (Dataset S1, Table S16). In
part this is due to the fact that analyzing two tissues allowed us to
identify germ-line (and discard somatic) heteroplasmies (51).
However, we also had to perform strict filtering of candidate
heteroplasmic sites to minimize sequencing artifacts when esti-
mating the bottleneck size—which may have led to the removal
of some real heteroplasmies. Our mtDNA mutation rate esti-
mate should therefore be seen as a “lower bound” (our bottle-
neck size estimate is not affected by this potential limitation). In
agreement with this, our estimate is only two- and fourfold
higher than estimates from mutation accumulation cell lines
for Caenorhabditis elegans and Drosophila melanogaster mtDNA
(9.7 × 10−8 and 6.2 × 10−8 mutations per site per generation,
respectively) (52, 53); human mutation rates were shown to be
approximately fivefold the rates in these species (54, 55).
Disease-Causing Mutations. The high prevalence of mtDNA dis-
ease-associated mutations found here—with one carrier in eight
individuals—is similar to that reported from the 1,000 Genomes
Project data (19) and has important practical implications. In-
deed, as we demonstrated, the severe germ-line bottleneck can
lead to drastic changes in allele frequencies between generations,
potentially affecting the manifestation of 200 diseases caused by
mtDNA mutations. In one instance we found a disease-associated
mutation present at high allele frequencies in child tissues. Ge-
netic background (both mtDNA and nuclear), known to signifi-
cantly modulate mtDNA disease manifestation (56), may be
preventing symptoms in this individual.
Materials and Methods
Sample Collection, DNA Isolation, and Sequencing. DNA from buccal and blood
cells (collected under IRB 30432EP) was isolated as described (32). To determine
mtDNA haplogroup, mtDNA was amplified and sequenced using the Sanger
method (Dataset S1, Table S17). Before MiSeq sequening, mtDNAwas amplified
in two ∼9-kb amplicons (16) that were mixed at an equimolar ratio and spiked
with 5% (wt/wt) of pUC18 or PhiX174 DNA, or with no spike-in. Sequencing
libraries were prepared according to the customized Nextera XT protocol (57).
Experimental Validation of Heteroplasmic Sites. The primers used for
heteroplasmy validation with Sanger sequencing are listed in Dataset S1, Table
S17. For ddPCR, we followed the manufacturer’s protocol. TaqMan probes are
listed in Dataset S1, Table S18. All experiments were performed in dupli-
cates. To assess the detection limit for ddPCR and Sanger sequencing, we
0
1
2
3
4
5
nu
m
be
r o
f p
oi
nt
 h
et
er
op
la
sm
ie
s
maternal age (years)
15 20 25 30 35 40 45 50 55 60
Poisson model
mother  p=0.04
child      p=0.01
fertilization collection
Fig. 2. Maternal age effect. The dependence of the total number of hetero-
plasmies (blue) in mothers on their age at collection and (red) in children on
maternal age at fertilization. Poisson generalized linear model fitted curves are
indicated.
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examined artificially mixed variant alleles at predetermined frequencies
(SI Materials and Methods).
Preprocessing of Next-Generation Sequencing Data. Parameters and versions
of all tools are listed in Dataset S1, Table S19. The sequencing read pairs were
mapped to chrM and hg19 (Fig. S4). For the pair to be retained, we required
both reads to (i) map to chrM, (ii) map properly in a pair, (iii) have read
length ≥100 bp, and (iv) not form a chimeric alignment.
Identification of Point Heteroplasmic Sites. The tools Naive Variant Caller and
Variant Annotator implemented in Galaxy (16) were used to extract the counts
of each nucleotide per position in each strand. We selected sites with MAF ≥1%
and depth ≥1,000× . We discarded sites with MAF <1% on one strand or with
strand bias >1 (58), low complexity regions as annotated in ref. 32, sites at
positions 3106–3107, and sites with the proportion of reads supporting an al-
ternative base within the first and last 25 bp >85%.
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